Agenus Inc (AGEN) - News Archive

Agenus Inc. Reports Q3 2025 Achievements: Regulatory Progress, New Data Revelations, and AI-Driven Collaborations LEXINGTON, Mass. Agenus Inc. (Nasdaq: AGEN) has announced its financial results for the third quarter of...

In the rapidly evolving field of immuno-oncology, Agenus Inc. (Nasdaq: AGEN) has marked a significant milestone with the presentation of new data demonstrating promising survival outcomes for patients with advanced-stag...

Accessing Hope: France Provides Compassionate Use for Agenus BOT/BAL Therapy in Colorectal CancerIn a groundbreaking development for cancer treatment, Agenus Inc. has announced that its innovative BOT/BAL combination th...

In a notable stride toward innovating cancer care, Agenus Inc. (Nasdaq: AGEN), a leading company in the immuno-oncology landscape, has showcased compelling data from its ongoing Phase 1 study focusing on botensilimab (B...

: The landscape of hepatocellular carcinoma (HCC) treatment continues to evolve with the ongoing developments in immuno-oncology. Agenus Inc. has made significant strides with its dual therapy of botensilimab (BOT) and...

In a world increasingly defined by its battle against cancer, innovations on the horizon remain a beacon of hope. Agenus Inc. (Nasdaq: AGEN), a trailblazer in the arena of immuno-oncology, is set to illuminate this fiel...

Agenus Inc. (Nasdaq: AGEN), a front-runner in the field of immuno-oncology, is making significant strides in the fight against cancer through its innovative therapies and ongoing research initiatives. The company recent...

Overview of Agenus in Immuno-Oncology Agenus Inc. (Nasdaq: AGEN), based in Lexington, Massachusetts, is making significant strides in the field of immuno-oncology, positioning itself as a frontrunner in cancer treatment...

Agenus Inc. a biopharmaceutical company focused on immuno-oncology, is at the forefront of innovation aimed at improving treatment responses for colorectal cancer. The Lexington, Massachusetts-based company recently ann...

: Agenus Inc. an innovative leader in the field of immuno-oncology, has recently showcased compelling data regarding their investigational immunotherapeutics, botensilimab (BOT) and balstilimab (BAL), at major oncology...

Agenus Inc. Secures a $22 Million Mortgage to Propel Strategic Growth Amid Operational Realignment In an ambitious move aimed at bolstering its financial footing, Agenus Inc. (Nasdaq: AGEN), a biopharmaceutical company...

Innovations Amidst Challenges: Agenus Inc. Reports on Strategic Advancements in Cancer Immunotherapy In an era where the fight against cancer has prompted remarkable advancements, Agenus Inc. (Nasdaq: AGEN) stands out w...

Unlocking New Horizons in Cancer Treatment: Agenus’ Promising Advances in ImmunotherapyIn an era defined by groundbreaking medical innovations, Agenus Inc. a pioneering leader in immunological cancer therapy, is making...

The biotechnology sector continues to experience volatility, and particularly in the case of Agenus Inc. (NASDAQ: AGEN), financial hardship has prompted significant concerns among investors. Recent reports have highligh...

The Efficacy of Botensilimab in Treatment-Resistant Cancers: Insights from Recent Research The development of novel immunotherapies has transformed the landscape of cancer treatment, particularly for advanced and treatm...

Combining Immunotherapy Agents BOT and BAL Shows Promising Results for Colorectal Cancer Treatment, Agenus ReportsLEXINGTON, Mass. - Agenus Inc. (NASDAQ: AGEN), a pioneer in the development of innovative immunological a...

Agenus Inc (NASDAQ: AGEN), a renowned leader in developing novel immunological agents to treat various cancers, has been experiencing a rather turbulent month in terms of stock performance. Despite its significant contr...

In recent weeks, Agenus Inc, a leader in developing immunological agents to treat various cancers, has seen its shares underperforming the overall market. However, an investigation into events and developments surroundi...

In recent years, substantial progress has been made in the field of immunotherapy for cancer treatment, revolutionizing the way we approach various malignancies. One such breakthrough is the combination of botensilimab...

Botensilimab: A Defining Force in the Future of Cancer Treatment Cancer therapy has always been at the forefront of medical research and development, aiming to unlock new possibilities that offer hope to millions facing...